ChromaVision and ACIS to be Featured At United States and Canadian Academy of Pathology Meeting.Business Editors & Health/Medical Writers SAN JUAN CAPISTRANO San Juan Capistrano (săn wän kăpĭsträ`nō), city (1990 pop. 26,183), Orange co., S Calif.; inc. 1961. San Juan Capistrano has some manufactures, including aircraft parts, medical apparatus, and boats, but the economy is , Calif.--(BW HealthWire)--March 20, 2000 ChromaVision Medical Systems Inc. (Nasdaq:CVSN), a unique cellular imaging systems company and manufacturer of the Automated Cellular Imaging System (ACIS(TM)) Monday announced that scientific data related to automated imaging and the ACIS will be presented at educational sessions at the 89th Annual Meeting of United States and Canadian Academy of Pathology (USCAP USCAP United States Climate Action Partnership USCAP United States and Canadian Academy of Pathology USCAP United States Commercial Aviation Partnership ) in New Orleans. Featured speakers will be Kenneth D. Bauer, Ph.D., vice president and chief science officer of the company and Douglas S. Harrington, M.D., CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and president of the company. The meeting will be held March 25 through March 31 at the New Orleans Hilton. Five separate scientific abstracts report uniformly positive results when the ChromaVision ACIS was used to test for bone marrow occult metastasis metastasis /me·tas·ta·sis/ (me-tas´tah-sis) pl. metas´tases 1. transfer of disease from one organ or part of the body to another not directly connected with it, due either to transfer of pathogenic microorganisms or to , HER2 protein expression and cytomegalovirus cytomegalovirus (sī'təmĕg'əlōvī`rəs), member of the herpesvirus family that can cause serious complications in persons with weakened immune systems. antigenemia. The abstracts were accepted for formal presentation at USCAP and have been published in the January 2000 volume of the peer-reviewed medical journal Modern Pathology. Authors of the ACIS-related abstracts include scientists and physicians from MD Anderson Cancer Center, University of Southern California The U.S. News & World Report ranked USC 27th among all universities in the United States in its 2008 ranking of "America's Best Colleges", also designating it as one of the "most selective universities" for admitting 8,634 of the almost 34,000 who applied for freshman admission School of Medicine, Emory University Medical School, independent pathology reference laboratories and ChromaVision. A hands-on ACIS demonstration will be available to USCAP attendees at ChromaVision's display booth in the meeting's technical exhibit hall. About ChromaVision Medical Systems ChromaVision Medical Systems has developed and markets a unique cellular imaging system designed to assist in the detection, diagnosis and treatment of cellular disease. The Automated Cellular Imaging System (ACIS(TM)) combines proprietary, color-based imaging technology with automated microscopy to bring unprecedented sensitivity, accuracy and reproducibility to the assessment of cell-based diseases such as cancer and infectious disease. ChromaVision currently markets its products to physicians and researchers in university medical centers and commercial laboratories throughout the world. ChromaVision Medical Systems was formed by XL Vision Inc. and is a Safeguard Scientifics Inc. (NYSE NYSE See: New York Stock Exchange :SFE See Sydney Futures Exchange. ) partnership company. For more information on ChromaVision Medical Systems visit the company's Web site at http://www.chromavision.com. The statements contained herein regarding ChromaVision Medical Systems Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to, uncertainty of success in developing any new diagnostic test, failure to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance or approval for particular applications and dependence on third parties for clinical testing. Note to Editors: ACIS is a trademark of ChromaVision Medical Systems Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion